Interstitial MR lymphography using Gd-carrying liposomes

Area of Science:

• Medical Imaging
• Nanotechnology
• Pharmacology

Background:

• Accurate detection of lymph node metastasis is crucial for cancer staging and treatment.
• Lymphography contrast agents enhance visualization of lymphatic pathways and lymph nodes.
• Current agents may have limitations in delivery or side effect profiles.

Purpose of the Study:

• To evaluate liposome-encapsulated gadobutrol as an interstitially injectable lymphography contrast agent.
• To assess the accumulation and tolerability of this novel agent in a preclinical animal model.
• To determine the suitability of this formulation for lymph node imaging.

Main Methods:

• An experimental animal model (guinea pig) was used for screening lymphotrophic compounds.
• Liposome-encapsulated gadobutrol was administered via subcutaneous injection into the interdigital skin fold of a hind limb.
• Gadolinium (Gd) concentration in successive lymph node groups was quantified 4 hours post-injection.

Main Results:

• Significant accumulation of gadobutrol was observed in popliteal (540 µmol/l), inguinal (260 µmol/l), and iliac (910 µmol/l) lymph nodes.
• The agent demonstrated high uptake, with up to 27% dose/g tissue in the iliac lymph nodes.
• The compound was completely eliminated and showed good tolerability in the animal model.

Conclusions:

• Liposome-encapsulated gadobutrol is a suitable candidate for interstitial lymphography.
• This formulation offers effective lymph node contrast enhancement with a favorable safety profile.
• Further research may explore its clinical application in detecting lymph node metastasis.